Diplomat Pharmacy Inc (DPLO) 29.53 $DPLO
Diplomat Extends Oncology Campaign to Honor Patients
PR Newswire - Tue Sep 06, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is extending its campaign to increase awareness of Diplomat in the oncology market and to honor patients who suffer from cancer, with a focus this month on multiple myeloma.
DPLO: 29.53 (+0.48)
Diplomat to Participate in Upcoming Investor Conferences
PR Newswire - Wed Aug 24, 1:00PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, chairman and CEO, and Sean Whelan, CFO, will present at four upcoming investor conferences.
DPLO: 29.53 (+0.48)
Diplomat to Dispense ZINBRYTA(TM) for the Treatment of Multiple Sclerosis
PR Newswire - Mon Aug 15, 7:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is now filling prescriptions for ZINBRYTA(TM) (daclizumab), which was recently approved by the Food and Drug Administration. ZINBRYTA is an interleukin-2 receptor-blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).
DPLO: 29.53 (+0.48)
Diplomat Announces 2nd Quarter Financial Results
PR Newswire - Tue Aug 09, 3:15PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended June 30, 2016. All comparisons, unless otherwise noted, are to the quarter ended June 30, 2015.
DPLO: 29.53 (+0.48)
Diplomat to Recognize Patients with World Hepatitis Day Campaign
PR Newswire - Thu Jul 28, 7:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is recognizing World Hepatitis Day with a campaign to raise awareness of the disease and honor patients who have felt its effects. World Hepatitis Day occurs annually July 28.
DPLO: 29.53 (+0.48)
Diplomat Launches Month-Long Campaign to Honor Cancer Patients
PR Newswire - Mon Jun 06, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is launching a month-long campaign to celebrate National Cancer Survivors Day and the people touched by the disease. The company also released a video highlighting one of their own patients' personal stories and her experience with acute myeloid leukemia.
DPLO: 29.53 (+0.48)
Why Investors Have This Drug Makers' Stocks on Their Radar? - Carbylan Therapeutics, Catalent Inc., Medicines Co., and Diplomat Pharmacy
PR Newswire - Mon Jun 06, 7:00AM CDT
The Generic Drugs space is an attractive yet very competitive industry. In today's lineup, ActiveWallSt.com have these companies: Carbylan Therapeutics Inc. (NASDAQ: CBYL), Catalent Inc. (NYSE: CTLT), The Medicines Co. (NASDAQ: MDCO), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks and receive your complimentary trade alerts at:
MDCO: 41.50 (+0.54), DPLO: 29.53 (+0.48), CTLT: 26.63 (+0.09), CBYL: 0.48 (+0.01)
Diplomat Completes Acquisition of TNH Advanced Specialty Pharmacy
PR Newswire - Wed Jun 01, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), announced today it has completed the acquisition of Valley Campus Pharmacy, Inc., doing business as TNH Advanced Specialty Pharmacy ("TNH"
, a leading specialty pharmacy that provides individualized patient care, based in Van Nuys, California.
DPLO: 29.53 (+0.48)
Diplomat to Host First "Diplomat Dialogue" in Honor of National Cancer Survivors Day
PR Newswire - Tue May 31, 3:36PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today its first "Diplomat Dialogue," a video conversation slated for June 7, 2016, to take a closer look at one patient's journey. The event, hosted live from noon to 1 p.m. ET, will focus on a man named Jay and the care team who helped him along the road to wellness.
DPLO: 29.53 (+0.48)
Diplomat to Participate in the William Blair 36th Annual Growth Stock Conference
PR Newswire - Tue May 31, 1:00PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, Chairman & CEO, and Sean Whelan, CFO, will present at the upcoming William Blair 36th Annual Growth Stock Conference in Chicago, IL.
DPLO: 29.53 (+0.48)
Diplomat Launches 3rd Annual Fellowship and Internship Programs
PR Newswire - Mon May 23, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the start of the third annual Fellowship and Internship programs. The hands-on learning experience is a 12-week summer program, May 23-Aug. 12.
DPLO: 29.53 (+0.48)
Diplomat's Hepatitis C Coverage Study with Penn Medicine Published and Chosen as Top Editor's Pick
PR Newswire - Wed May 18, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced the publication of its collaborative study with the Perelman School of Medicine at the University of Pennsylvania on insurance coverage for hepatitis C.
DPLO: 29.53 (+0.48)
Smith Drug Company Partners With Diplomat Pharmacy Inc. to Bring Specialty Pharmacy to Independent Retail Pharmacies
Marketwired - Mon May 16, 8:20AM CDT
Customers Can Now Offer Comprehensive Patient Care and Clinical Expertise for Specialty Prescriptions
DPLO: 29.53 (+0.48)
Diplomat Pharmaceuticals posts 1Q profit
Automated Insights - Mon May 09, 3:53PM CDT
FLINT, Mich. (AP) _ Diplomat Pharmacy Inc. (DPLO) on Monday reported first-quarter net income of $15.4 million.
DPLO: 29.53 (+0.48)
Diplomat Announces 1st Quarter Financial Results
PR Newswire - Mon May 09, 3:15PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended March 31, 2016. All comparisons, unless otherwise noted, are to the quarter ended March 31, 2015.
DPLO: 29.53 (+0.48)
Diplomat Celebrates World Hepatitis Month with National Multimedia Campaign
PR Newswire - Tue May 03, 8:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to honor patients and caregivers. The company released a video of two patients who tell their personal story and encourage those at risk to get tested and begin the road to a life free of hepatitis.
DPLO: 29.53 (+0.48)
Diplomat to Acquire Oncology-Focused TNH Advanced Specialty Pharmacy
PR Newswire - Thu Apr 28, 3:30PM CDT
Click here for supplemental information regarding the transaction. Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced today that it has signed a definitive agreement to acquire Valley Campus Pharmacy, Inc., doing business as TNH Advanced Specialty Pharmacy ("TNH", a leading specialty pharmacy that provides individualized patient care, based in Van Nuys, California. In 2015, TNH generated approximately $400 million in revenue. The transaction is expected to close in the next 30 to 60 days and is expected to be accretive to Diplomat's earnings per share in 2016.
DPLO: 29.53 (+0.48)
Diplomat Announces Executive Promotion for Jennifer Hagerman
PR Newswire - Tue Apr 26, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased to announce the promotion of Jennifer Hagerman, Pharm D., to Vice President of Education and Quality.
DPLO: 29.53 (+0.48)
Diplomat to Dispense VENCLEXTA(TM) for the Treatment of Chronic Lymphocytic Leukemia
PR Newswire - Tue Apr 19, 7:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is now filling prescriptions for VENCLEXTA(TM) (venetoclax). VENCLEXTA(TM) was recently approved by the U.S. Food and Drug Administration for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion.
DPLO: 29.53 (+0.48)
Diplomat Extends Oncology Campaign to Honor Patients
PR Newswire - Tue Sep 06, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is extending its campaign to increase awareness of Diplomat in the oncology market and to honor patients who suffer from cancer, with a focus this month on multiple myeloma.
DPLO: 29.53 (+0.48)
Diplomat to Participate in Upcoming Investor Conferences
PR Newswire - Wed Aug 24, 1:00PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, chairman and CEO, and Sean Whelan, CFO, will present at four upcoming investor conferences.
DPLO: 29.53 (+0.48)
Diplomat to Dispense ZINBRYTA(TM) for the Treatment of Multiple Sclerosis
PR Newswire - Mon Aug 15, 7:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is now filling prescriptions for ZINBRYTA(TM) (daclizumab), which was recently approved by the Food and Drug Administration. ZINBRYTA is an interleukin-2 receptor-blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).
DPLO: 29.53 (+0.48)
Diplomat Announces 2nd Quarter Financial Results
PR Newswire - Tue Aug 09, 3:15PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended June 30, 2016. All comparisons, unless otherwise noted, are to the quarter ended June 30, 2015.
DPLO: 29.53 (+0.48)
Diplomat to Recognize Patients with World Hepatitis Day Campaign
PR Newswire - Thu Jul 28, 7:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is recognizing World Hepatitis Day with a campaign to raise awareness of the disease and honor patients who have felt its effects. World Hepatitis Day occurs annually July 28.
DPLO: 29.53 (+0.48)
Diplomat Launches Month-Long Campaign to Honor Cancer Patients
PR Newswire - Mon Jun 06, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is launching a month-long campaign to celebrate National Cancer Survivors Day and the people touched by the disease. The company also released a video highlighting one of their own patients' personal stories and her experience with acute myeloid leukemia.
DPLO: 29.53 (+0.48)
Why Investors Have This Drug Makers' Stocks on Their Radar? - Carbylan Therapeutics, Catalent Inc., Medicines Co., and Diplomat Pharmacy
PR Newswire - Mon Jun 06, 7:00AM CDT
The Generic Drugs space is an attractive yet very competitive industry. In today's lineup, ActiveWallSt.com have these companies: Carbylan Therapeutics Inc. (NASDAQ: CBYL), Catalent Inc. (NYSE: CTLT), The Medicines Co. (NASDAQ: MDCO), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks and receive your complimentary trade alerts at:
MDCO: 41.50 (+0.54), DPLO: 29.53 (+0.48), CTLT: 26.63 (+0.09), CBYL: 0.48 (+0.01)
Diplomat Completes Acquisition of TNH Advanced Specialty Pharmacy
PR Newswire - Wed Jun 01, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), announced today it has completed the acquisition of Valley Campus Pharmacy, Inc., doing business as TNH Advanced Specialty Pharmacy ("TNH"
, a leading specialty pharmacy that provides individualized patient care, based in Van Nuys, California. DPLO: 29.53 (+0.48)
Diplomat to Host First "Diplomat Dialogue" in Honor of National Cancer Survivors Day
PR Newswire - Tue May 31, 3:36PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today its first "Diplomat Dialogue," a video conversation slated for June 7, 2016, to take a closer look at one patient's journey. The event, hosted live from noon to 1 p.m. ET, will focus on a man named Jay and the care team who helped him along the road to wellness.
DPLO: 29.53 (+0.48)
Diplomat to Participate in the William Blair 36th Annual Growth Stock Conference
PR Newswire - Tue May 31, 1:00PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, has announced that Phil Hagerman, Chairman & CEO, and Sean Whelan, CFO, will present at the upcoming William Blair 36th Annual Growth Stock Conference in Chicago, IL.
DPLO: 29.53 (+0.48)
Diplomat Launches 3rd Annual Fellowship and Internship Programs
PR Newswire - Mon May 23, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the start of the third annual Fellowship and Internship programs. The hands-on learning experience is a 12-week summer program, May 23-Aug. 12.
DPLO: 29.53 (+0.48)
Diplomat's Hepatitis C Coverage Study with Penn Medicine Published and Chosen as Top Editor's Pick
PR Newswire - Wed May 18, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced the publication of its collaborative study with the Perelman School of Medicine at the University of Pennsylvania on insurance coverage for hepatitis C.
DPLO: 29.53 (+0.48)
Smith Drug Company Partners With Diplomat Pharmacy Inc. to Bring Specialty Pharmacy to Independent Retail Pharmacies
Marketwired - Mon May 16, 8:20AM CDT
Customers Can Now Offer Comprehensive Patient Care and Clinical Expertise for Specialty Prescriptions
DPLO: 29.53 (+0.48)
Diplomat Pharmaceuticals posts 1Q profit
Automated Insights - Mon May 09, 3:53PM CDT
FLINT, Mich. (AP) _ Diplomat Pharmacy Inc. (DPLO) on Monday reported first-quarter net income of $15.4 million.
DPLO: 29.53 (+0.48)
Diplomat Announces 1st Quarter Financial Results
PR Newswire - Mon May 09, 3:15PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended March 31, 2016. All comparisons, unless otherwise noted, are to the quarter ended March 31, 2015.
DPLO: 29.53 (+0.48)
Diplomat Celebrates World Hepatitis Month with National Multimedia Campaign
PR Newswire - Tue May 03, 8:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign to honor patients and caregivers. The company released a video of two patients who tell their personal story and encourage those at risk to get tested and begin the road to a life free of hepatitis.
DPLO: 29.53 (+0.48)
Diplomat to Acquire Oncology-Focused TNH Advanced Specialty Pharmacy
PR Newswire - Thu Apr 28, 3:30PM CDT
Click here for supplemental information regarding the transaction. Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced today that it has signed a definitive agreement to acquire Valley Campus Pharmacy, Inc., doing business as TNH Advanced Specialty Pharmacy ("TNH"
, a leading specialty pharmacy that provides individualized patient care, based in Van Nuys, California. In 2015, TNH generated approximately $400 million in revenue. The transaction is expected to close in the next 30 to 60 days and is expected to be accretive to Diplomat's earnings per share in 2016. DPLO: 29.53 (+0.48)
Diplomat Announces Executive Promotion for Jennifer Hagerman
PR Newswire - Tue Apr 26, 3:30PM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased to announce the promotion of Jennifer Hagerman, Pharm D., to Vice President of Education and Quality.
DPLO: 29.53 (+0.48)
Diplomat to Dispense VENCLEXTA(TM) for the Treatment of Chronic Lymphocytic Leukemia
PR Newswire - Tue Apr 19, 7:00AM CDT
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is now filling prescriptions for VENCLEXTA(TM) (venetoclax). VENCLEXTA(TM) was recently approved by the U.S. Food and Drug Administration for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion.
DPLO: 29.53 (+0.48)
